135 related articles for article (PubMed ID: 32993564)
21. EGFR mutation: novel prognostic factor associated with immune infiltration in lower-grade glioma; an exploratory study.
Hao Z; Guo D
BMC Cancer; 2019 Dec; 19(1):1184. PubMed ID: 31801484
[TBL] [Abstract][Full Text] [Related]
22. Molecular and clinical characterization of TMEM71 expression at the transcriptional level in glioma.
Wang KY; Huang RY; Tong XZ; Zhang KN; Liu YW; Zeng F; Hu HM; Jiang T
CNS Neurosci Ther; 2019 Sep; 25(9):965-975. PubMed ID: 31180187
[TBL] [Abstract][Full Text] [Related]
23. Reduced expression of microRNA-497 is associated with greater angiogenesis and poor prognosis in human gliomas.
Feng F; Kuai D; Wang H; Li T; Miao W; Liu Y; Fan Y
Hum Pathol; 2016 Dec; 58():47-53. PubMed ID: 27569294
[TBL] [Abstract][Full Text] [Related]
24. PLEKHG5 is a novel prognostic biomarker in glioma patients.
Qian M; Chen Z; Wang S; Guo X; Zhang Z; Qiu W; Gao X; Xu J; Zhao R; Xue H; Li G
Int J Clin Oncol; 2019 Nov; 24(11):1350-1358. PubMed ID: 31309383
[TBL] [Abstract][Full Text] [Related]
25. Identification of Periostin as a Potential Biomarker in Gliomas by Database Mining.
Faried A; Hermanto Y; Tjahjono FP; Valentino A; Arifin MZ
World Neurosurg; 2020 Mar; 135():e137-e163. PubMed ID: 31785437
[TBL] [Abstract][Full Text] [Related]
26. Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status.
Cheng W; Ren X; Zhang C; Han S; Wu A
J Neurooncol; 2017 Apr; 132(2):207-218. PubMed ID: 28091987
[TBL] [Abstract][Full Text] [Related]
27. Loss of 5'-Methylthioadenosine Phosphorylase (MTAP) is Frequent in High-Grade Gliomas; Nevertheless, it is Not Associated with Higher Tumor Aggressiveness.
Menezes WP; Silva VAO; Gomes INF; Rosa MN; Spina MLC; Carloni AC; Alves ALV; Melendez M; Almeida GC; Silva LSD; Clara C; da Cunha IW; Hajj GNM; Jones C; Bidinotto LT; Reis RM
Cells; 2020 Feb; 9(2):. PubMed ID: 32093414
[TBL] [Abstract][Full Text] [Related]
28. ACTC1 as an invasion and prognosis marker in glioma.
Ohtaki S; Wanibuchi M; Kataoka-Sasaki Y; Sasaki M; Oka S; Noshiro S; Akiyama Y; Mikami T; Mikuni N; Kocsis JD; Honmou O
J Neurosurg; 2017 Feb; 126(2):467-475. PubMed ID: 27081897
[TBL] [Abstract][Full Text] [Related]
29. An integrated transcriptomic and computational analysis for biomarker identification in human glioma.
Xing W; Zeng C
Tumour Biol; 2016 Jun; 37(6):7185-92. PubMed ID: 26663173
[TBL] [Abstract][Full Text] [Related]
30. High CHI3L1 expression is associated with glioma patient survival.
Steponaitis G; Skiriutė D; Kazlauskas A; Golubickaitė I; Stakaitis R; Tamašauskas A; Vaitkienė P
Diagn Pathol; 2016 Apr; 11():42. PubMed ID: 27121858
[TBL] [Abstract][Full Text] [Related]
31. FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas.
Yan J; Kong LY; Hu J; Gabrusiewicz K; Dibra D; Xia X; Heimberger AB; Li S
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971300
[TBL] [Abstract][Full Text] [Related]
32. Downregulation of microRNA-504 is associated with poor prognosis in high-grade glioma.
Guan Y; Chen L; Bao Y; Pang C; Cui R; Li G; Liu J; Wang Y
Int J Clin Exp Pathol; 2015; 8(1):727-34. PubMed ID: 25755767
[TBL] [Abstract][Full Text] [Related]
33. Integrated profiling identifies caveolae-associated protein 1 as a prognostic biomarker of malignancy in glioblastoma patients.
Guo Q; Guan GF; Cheng W; Zou CY; Zhu C; Cheng P; Wu AH
CNS Neurosci Ther; 2019 Mar; 25(3):343-354. PubMed ID: 30311408
[TBL] [Abstract][Full Text] [Related]
34. Differential expression of microRNA-210 in gliomas of variable cell origin and correlation between increased expression levels and disease progression in astrocytic tumours.
Lai N; Zhu H; Chen Y; Zhang S; Zhao X; Lin Y
Folia Neuropathol; 2014; 52(1):79-85. PubMed ID: 24729345
[TBL] [Abstract][Full Text] [Related]
35. The promising novel biomarkers and candidate small molecule drugs in lower-grade glioma: Evidence from bioinformatics analysis of high-throughput data.
Zhang B; Wu Q; Xu R; Hu X; Sun Y; Wang Q; Ju F; Ren S; Zhang C; Qi F; Ma Q; Wang Z; Zhou YL
J Cell Biochem; 2019 Sep; 120(9):15106-15118. PubMed ID: 31020692
[TBL] [Abstract][Full Text] [Related]
36. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
37. RAB38 confers a poor prognosis, associated with malignant progression and subtype preference in glioma.
Wang H; Jiang C
Oncol Rep; 2013 Nov; 30(5):2350-6. PubMed ID: 24026199
[TBL] [Abstract][Full Text] [Related]
38. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
39. RAB34 was a progression- and prognosis-associated biomarker in gliomas.
Wang HJ; Gao Y; Chen L; Li YL; Jiang CL
Tumour Biol; 2015 Mar; 36(3):1573-8. PubMed ID: 25501506
[TBL] [Abstract][Full Text] [Related]
40. Cell division cycle associated 7 like predicts unfavorable prognosis and promotes invasion in glioma.
Shen FZ; Li XS; Ma JW; Wang XY; Zhao SP; Meng L; Liang SF; Zhao XL
Pathol Res Pract; 2019 Jan; 215(1):50-56. PubMed ID: 30389317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
